For sales

📢 Highlights from April 14 to 18 in the world of pharma and healthcare! 🗞️👀

Vyuhpharma Celltrion (FDA, Phase 3) Celltrion's YUFLYMA receives FDA interchangeable designation, supported by positive Phase 3 study data for moderate-to-severe plaque psoriasis Wayfinder Bioscinces + Daiichi Sankyo (Collaboration) "Wayfinder and Daiichi Sankyo have announced an R&D collaboration in neurodegeneration Eli Lilly (Clinical data, Phase 3) Lilly's oral GLP-1, orforglipron, has met its primary endpoints in a Phase 3 trial, demonstrating significant efficacy and safety comparable to injectable GLP-1 therapies Sanofi + Earendil Labs (Agreement) "Earendil Labs and Sanofi have entered into a license agreement for two potential first-in-class bispecific atibodies, HXN-1002 and HXN-1003, targeting autoimmune and inflammatory bowel diseases All logos and trademarks remain the intellectual properties of their respective owners
Download

Connect with us

Please fill in the information below, and we'll get back to you.